Abstract: Antibodies and fragments thereof have high affinity for human ?-synuclein protofibrils and low binding of ?-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting ?-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with ?-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with ?-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with ?-synuclein pathology, and in methods for reducing or inhibiting ?-synuclein aggregation by administration of such an antibody or fragment.
Type:
Application
Filed:
August 28, 2014
Publication date:
December 11, 2014
Inventors:
Eva Nordström, Alex Kasrayan, Monica Ekberg, Valentina Screpanti Sundquist, Lars Lannfelt, Mats Holmquist
Abstract: The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids.
Type:
Application
Filed:
July 24, 2014
Publication date:
December 11, 2014
Inventors:
Magnus VON KNEBEL-DOEBERITZ, Johannes Gebert, Michael Linnebacher, Stefan Woerner, Ruediger Ridder, Peer Bork, Yan Ping Yuan
Abstract: The present invention provides for sonication-assisted metal-enhanced fluorescence, luminescence, and/or chemiluminescence assay systems using low-intensity ultrasound waves to significantly reduce the assay time by increasing the kinetic movement of molecules within the system.
Type:
Grant
Filed:
September 11, 2009
Date of Patent:
December 9, 2014
Assignee:
University of Maryland, Baltimore County
Abstract: Methods of diagnosing Clostridium difficile infection and compounds used in the methods are provided. The diagnostic methods are specific and sensitive methods for detecting a host cell response and, in some aspects, a target response, i.e. a Clostridium difficile toxin, in an individual infected with Clostridium difficile. The methods comprise detecting in a stool specimen or fluid exposed to the stool specimen a Clostridium difficile toxin, or a fragment thereof, and an increase in a colonic epithelial cell protein exemplified by a non-muscle tropomyosin. Also provided are kits comprising reagents for detecting host cell proteins and Clostridium difficile toxins.
Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
Type:
Grant
Filed:
December 20, 2011
Date of Patent:
December 9, 2014
Assignee:
Randox Laboratories Limited
Inventors:
Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
Abstract: A method for immobilizing an amino-containing material to a substrate is described. The method involves providing a tethering compound with two reactive groups: a substrate reactive group and a fluoroalkoxycarbonyl group. The method further involves preparing a substrate-attached tethering group by reacting the substrate reactive group of the tethering compound with a complementary functional group on the surface of a substrate. The substrate-attached tethering group has a fluoroalkoxycarbonyl group that can be reacted with an amino-containing material to form an immobilization group that connects the amino-containing material to the substrate.
Type:
Grant
Filed:
September 17, 2007
Date of Patent:
December 9, 2014
Assignee:
3M Innovative Properties Company
Inventors:
Karl E. Benson, Charles M. Leir, George G. I. Moore, Rahul R. Shah
Abstract: Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-a (CHEF1) promoter, which may be used in the methods provided herein.
Type:
Application
Filed:
August 13, 2014
Publication date:
December 4, 2014
Inventors:
Randal J. KAUFMAN, Steven W. Pipe, Michael GRIFFITH
Abstract: The present invention relates to a method of determining vascular health in a subject. The method includes the steps of obtaining a biological sample from the subject, obtaining microparticle data based on the level of at least one set of microparticles in the biological sample, obtaining progenitor cell data based on the level of at least one set of progenitor cells in the biological sample, generating a cytometric fingerprint of the biological sample based on the microparticle and progenitor cell data, and determining the vascular health of the subject based on the generated cytometric fingerprint.
Type:
Application
Filed:
June 10, 2012
Publication date:
December 4, 2014
Applicant:
The Trustees of the University of Pennsylvania
Inventors:
Emile R. Mohler, III, Jonni S. Moore, Lifeng Zhang, Wade Rogers, Andrew D. Bantly
Abstract: Disclosed are a method for measuring ?G comprising the steps of bringing a sample into contact with a ?G-binding protein 1 and a ?G-binding protein 2, each comprising an amino acid sequence which is identical or substantially identical to an amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20, and having the ?-glucan binding activity, to form a complex of the ?G-binding protein 1, ?G in the sample and the ?G-binding protein 2, measuring quantity of the complex, and determining ?G concentration in the sample based on the quantity of the complex; a reagent and a kit for use in said method; a novel ?G-binding protein; a nucleic acid molecule encoding the ?G-binding protein; and a method for producing the aforementioned ?G-binding protein.
Abstract: The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of NFkB, as measured by a H-score of the patient's nasopharyngeal cancer tumor sample using a “NFkB p65 IHC assay. The invention also provides a method of determining whether to treat a patient with the compound of formula (I) based on the level of NFkB p65 in the patient's nasopharyngeal cancer tumor sample.
Type:
Application
Filed:
January 23, 2013
Publication date:
December 4, 2014
Inventors:
Stephen J. Blakemore, Alessandra M. Di Bacco, George J. Mullingan
Abstract: Provided is a method of suppressing resistance to an anticancer drug, comprising administering an inhibitor of expression or activity of ECM 1 (Extracellular Matrix Protein 1) to a cancer cell or an individual with cancer.
Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
Type:
Application
Filed:
August 20, 2014
Publication date:
December 4, 2014
Applicant:
BioAtla LLC
Inventors:
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Abstract: Diagnostic, prognostic, and treatment methods, compositions, and kits for enhancing insulin secretion and beta cell numbers and functions, and controlling glycemia associated with diabetes, obesity, atherosclerosis, stroke, myocardial infarction, and other cardiovascular diseases, by modulating FKN/CX3CR1 expression levels or activities, and its downstream signaling pathways in a subject in need or at risk.
Abstract: The present invention relates to novel peptides that may be used in whole or in combination for the detection of Mycobacterium tuberculosis infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from M. tuberculosis or vaccination using an epitope specific inoculation. More particularly, the present invention provides a means to distinguish early, active, and latent M. tuberculosis infection. More particularly, the present invention describes an immunological diagnostic mechanism for the detection of M. tuberculosis infection.
Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
Type:
Application
Filed:
August 13, 2014
Publication date:
December 4, 2014
Inventors:
NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
Abstract: The present invention is directed to a method of diagnosis and prognostication of a hepatobiliary tumor, the method comprising the step of determining expression of MACC1 polypeptide or of a nucleic acid encoding said MACC1 polypeptide in a biological sample.
Type:
Application
Filed:
May 30, 2014
Publication date:
December 4, 2014
Inventors:
Ulrike STEIN, Peter M. SCHLAG, Andri LEDERER, Daniel SEEHOFER, Pia HERMANN
Abstract: The present disclosure provides a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein and a kit for radiation exposure diagnosis. Methods of diagnosing radiation exposure as well as methods for screening an agent for enhancing radiation sensitivity or for radiation protection are disclosed. Also provided are compositions for enhancing radiation sensitivity and/or radiation protection.
Type:
Application
Filed:
May 9, 2012
Publication date:
December 4, 2014
Applicant:
Korea Institute of Radiological & Medical Sciences
Inventors:
Kwang Seok Kim, Sang Woo Bae, Kyu Jin Choi, Eun Sook Kim
Abstract: High affinity antibodies for binding epitopes of BoNT/B and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/B in a sample.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
December 2, 2014
Assignee:
The United States of America, as represented by the Secretary of Agriculture
Inventors:
Larry H. Stanker, Miles C. Scotcher, Luisa W. Cheng, Robert M. Hnasko, Jeffery A. McGarvey
Abstract: In the case of assaying the level of complex AB in a sample which likely contains the complex AB composed of substance A with another substance B, the complex is assayed by the competitive homogeneous assay method with the use of reagents including a reagent containing partner C specifically binding to substance A, a reagent containing partner D specifically binding to substance B, a reagent containing fine particles carrying substance A or an analog thereof and substance B or an analog thereof, and a reagent containing partner C specifically binding to substance A and partner D specifically binding to substance B. Thus, the complex in the sample can be easily assayed. The above method is applicable to general-purpose biochemical automatic analyzers.
Type:
Grant
Filed:
May 14, 2009
Date of Patent:
December 2, 2014
Assignees:
Nitto Boseki Co., Ltd., Shinshu University
Inventors:
Kiyotaka Fujita, Ryo Kojima, Yoshiro Sato, Natsuki Sato
Abstract: The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications.
Type:
Grant
Filed:
June 11, 2009
Date of Patent:
December 2, 2014
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Jacob Victor, Noah Berkowitz, Andrew Levy
Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.
Type:
Grant
Filed:
December 29, 2011
Date of Patent:
December 2, 2014
Assignee:
RSR Limited
Inventors:
Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
Abstract: The present invention provides a method of detecting or measuring trans-Resveratrol (tRV) in a sample, comprising: contacting a sample to be tested with an antibody against tRV, or an antigen binding fragment of such an antibody; and detecting or measuring any tRV bound by the antibody or antibody fragment. The invention also provides an antibody against trans-Resveratrol.
Abstract: An object of the present invention is to provide an immunoassay method and an immunoassay kit which have the excellent effect of producing enhanced measurement sensitivity and yet reduced non-specific reaction. An immunoassay method including performing immune reaction in the presence of 0.67 to 2.67% (W/V) of chondroitin sulfate and 3.5% (W/V) or more of sodium chloride is provided.
Abstract: Disclosed are methods and kits for pharmacokinetic profiling employing point-of-care or point of service self-sampling and allowing for dosage adjustments based on the pharmacokinetic profiles.
Abstract: Assays for detecting anti-streptococcal antibodies in biological samples using one or more streptococcal antigens are described herein. Various combinations of antigens may be used in the assays. For example, one or more of Ply, PhtD, PhtE, LytB and PcpA may be utilized. Additional streptococcal antigens may also be used. The assays may also be used in combination with assays that detect streptococcal nucleic acids.
Type:
Application
Filed:
March 1, 2013
Publication date:
November 27, 2014
Applicant:
Sanofi Pasteur Limited
Inventors:
Martina Ochs-Onolemhemhen, Roger Brookes, Claire-Anne Siegrest
Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
Type:
Application
Filed:
September 10, 2012
Publication date:
November 27, 2014
Applicant:
UCB PHARMA S.A.
Inventors:
David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenze, Matthew Cox
Abstract: The present invention provides novel radiation associated markers. The radiation associated markers may be one or more of albumin, LTGF-?, or any protein or peptide listed in any one of Tables 1, 2, 3, 4, 5, and 6 provided herein. The present invention also provides methods of assessing exposure to ionizing radiation by determining the presence of one or more radiation associated markers. The methods may optionally include quantifying one or more of the radiation associated markers. The methods may further include comparing the amount of one or more radiation associated markers in the sample determined to be present in the sample with either (i) the amount determined for temporally matched, normal samples or (ii) the amount determined for samples obtained from individuals or subjects that have not been exposed to an elevated level of ionizing radiation.
Abstract: Methods are described for using genes crucial in TH17 differentiation, IL-12Rbeta 1/IL-23R, CCR6, BATF, AHR, STAT3 and IRF4 as new markers for rosacea. Also described, are methods of their use to diagnose rosacea, to screen inhibitors of Th17 differentiation. In particular, method are described for inhibiting at least one of these genes and using the screened inhibitors in rosacea treatment.
Abstract: The subject invention pertains to materials and methods for diagnosing and/or predicting pathologic infant conditions. A method of the invention comprises obtaining a biological sample from an infant and analyzing the sample to detect at least one protein biomarker of necrotizing enterocolitis (NEC), wherein a patient is diagnosed with NEC or determined to have a likelihood of developing NEC following detection of the biomarker. In another method of the invention, the likelihood of a patient developing NEC is determined. In certain embodiments, treatment is administered to the patient following diagnosis of NEC or determination that the patient has a likelihood of developing NEC.
Abstract: The present invention is concerned with tools for the quality control and safety during manufacture of neurotoxins. In particular, it relates to a method for the determination of the amount of partially processed and/or unprocessed Botulinum neurotoxin A polypeptide (BoNT/A) in a solution comprising processed and partially processed and/or unprocessed BoNT/A comprising the steps of contacting a sample of the solution with a capture antibody which specifically binds to the partially processed and unprocessed BoNT/A under conditions which allow for binding of the antibody to the partially processed and unprocessed BoNT/A, whereby a complex is formed, and determining the amount of the formed complex, whereby the amount of the complex is indicative for the amount of the partially processed and/or unprocessed BoNT/A in the solution. Moreover, the present invention contemplates a device and a kit for carrying out the method.
Type:
Application
Filed:
August 13, 2014
Publication date:
November 27, 2014
Inventors:
Harold Victor TAYLOR, Karl-Heinz Eisele, Cornelia Brunn
Abstract: Biomarkers of Kawasaki Disease (KD) are provided. In certain aspects, methods are provided for detecting KD biomarkers, such as elevated PDGFC expression. Likewise, methods of treating a subject having a biomarker of KD are described.
Type:
Application
Filed:
December 21, 2012
Publication date:
November 27, 2014
Inventors:
Virginia M. Pascual, Zhaohui Xu, Octavio Ramilo, Rolando Cimaz
Abstract: The present invention relates to a three dimensional (or 3D) microfluidic system comprising a plurality of layers stacked upon each other, characterised in that at least one of said layers consists of a 1st and at least one 2nd parts, distinct from each other, with the 2nd part being porous and wettable by a solution of interest, nesting into a recess of the 1st part being non-porous and/or non-wettable by said solution of interest, wherein said system can possibly have a built-in reservoir; a method for manufacturing the same and different uses thereof.
Abstract: A use of tumor necrosis factor (TNF) receptor-associated factor 7 (TRAF7) as a biomarker for systemic lupus erythematosus (SLE) and a method and a kit for detecting human with SLE are provided. The kit for detecting human with SLE includes TRAF7 and anti-TRAF7 antibodies. The method for detecting human with SLE includes the following steps. A plasma sample is taken from a patient with suspected SLE. The ratio of TRAF7 to total protein in the plasma sample of the patient is compared with that in the plasma sample of normal people. If the ratio of TRAF7 to total protein in the plasma sample of the patient is higher than that of the normal people, then it is possible that the patient is suffering from SLE. TRAF7 can be used as a biomarker for SLE patients in active phase and with renal involvement.
Type:
Application
Filed:
November 26, 2013
Publication date:
November 27, 2014
Applicant:
National Central University
Inventors:
Shir-Ly Huang, Shin-Chang Lin, Wei-Hsin Sun
Abstract: The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AML1-ETO acetylation. The present invention further provides methods of using these treatments.
Abstract: The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such as cancer, influenza virus, hepatitis C virus and RSV (respiratory syncytial virus) by enhancing immune responses.
Abstract: A method is described for the diagnosis of rosacea. The method can include a step of measuring the expression of at least one peptide from the galanin family in a sample of biological fluid from a patient. Also described, is a related diagnostic kit.
Abstract: The invention also relates to the use of these complex forms for the purposes of screening for biological or chemical compounds capable of modulating a biological activity of said complex forms and/or for preparing and/or improving a pluristratified cell model.
Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.
Abstract: The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.
Abstract: The present invention relates to a method of using adaptive immunity to detect drug resistance in infectious diseases. The invention provides novel antigens associated with drug resistant MTB infection.
Type:
Application
Filed:
December 17, 2012
Publication date:
November 27, 2014
Inventors:
Gregory P. Bisson, Drew Weissman, Harvey Rubin
Abstract: A chemo-mechano-chemical (C1-M-C2) system includes a base supporting an actuatable structure, said structure comprising a functionalized portion and being embedded in an environmentally responsive gel capable of volume change in response to an environmental stimulus; a first fluid layer disposed over the base and in contact with the actuatable structure, said first fluid layer comprising the environmentally responsive gel; and a second fluid layer in contact with the actuatable structure, wherein the layers are positioned such that the functionalized portion is in contact with the second layer in a first relaxed state and in contact with the first layer in a second actuated state and wherein the functionalized portion interacts with at least one of the layers to provide a chemical or physical response.
Type:
Application
Filed:
May 2, 2014
Publication date:
November 27, 2014
Applicant:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Joanna AIZENBERG, Ximin HE, Michael AIZENBERG
Abstract: The present invention relates to a method of identifying candidate compounds useful as chemotherapeutics or anti-infective compounds or anti-inflammatory drugs. This method involves providing a plurality of test compounds. The plurality of test compounds are incubated with human Regulatory T (Treg) cells expressing Disc-Large Homo log 1 (Dlgh1) or in which Dlgh1 is suppressed, where the Treg cells have an immunological synapse (IS). Test compounds which inhibit Dlgh1 expression, recruitment to the IS, and/or activity in the Treg cells are identified as candidate compounds potentially useful as chemotherapeutics or anti-infective compounds. Test compounds which enhance Dlgh1 recruitment to the IS and/or activity in the Treg cells are identified as candidate compounds potentially useful as anti-inflammatory drugs. The present invention also relates to methods of treating inflammatory conditions, cancers, and infectious diseases in a subject, as well as methods of inhibiting Treg cell activity.
Abstract: Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.
Type:
Application
Filed:
March 13, 2014
Publication date:
November 27, 2014
Applicant:
Promega Corporation
Inventors:
Andrew S. Dixon, Lance Encell, Mary Hall, Keith Wood, Monika Wood, Marie Schwinn, Brock F. Binkowski, Hicham Zegzouti, Nidhi Nath, Subhanjan Mondal, Said Goueli, Poncho Meisenheimer, Thomas Kirkland, James Unch, Dileep K. Pulukkunat, Matthew Robers, Melanie Dart, Thomas Machleidt
Abstract: The invention lies in the area of platelet function diagnostics and relates to an in vitro method for the determination of platelet function under flow conditions. The method is particularly suitable for the determination of the effect of clopidogrel after oral intake and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) receptor antagonists with antithrombotic activity.
Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
Type:
Application
Filed:
October 1, 2012
Publication date:
November 20, 2014
Applicant:
Ablynx N.V.
Inventors:
Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
Abstract: The present invention pertains to the field of diagnostics for gonadal toxicity and toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing gonadal toxicity. It also relates to a method for determining whether a compound is capable of inducing such gonadal toxicity in a subject and to a method of identifying a drug for treating gonadal toxicity. Furthermore, the present invention relates to a device and a kit for diagnosing gonadal toxicity.
Type:
Application
Filed:
September 14, 2012
Publication date:
November 20, 2014
Applicant:
BASF SE
Inventors:
Tilman B. Walk, Bennard van Ravenzwaay, Werner Mellert, Eric Fabian, Volker Strauss, Hennicke Kamp, Jan C. Wiemer, Ralf Looser, Michael Manfred Herold, Alexandre Prokoudine